Genelink Inc (GNLKQ)
0.00
USD |
OTCM |
May 31, 16:00
Genelink Max Drawdown (5Y): 99.99% for May 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
Date | Value |
---|---|
May 31, 2024 | 99.99% |
April 30, 2024 | 99.99% |
March 31, 2024 | 99.99% |
February 29, 2024 | 99.99% |
January 31, 2024 | 99.99% |
December 31, 2023 | 99.99% |
November 30, 2023 | 99.99% |
October 31, 2023 | 99.99% |
September 30, 2023 | 99.99% |
August 31, 2023 | 99.99% |
July 31, 2023 | 99.99% |
June 30, 2023 | 99.99% |
May 31, 2023 | 99.99% |
April 30, 2023 | 99.99% |
March 31, 2023 | 99.99% |
February 28, 2023 | 99.99% |
January 31, 2023 | 99.99% |
December 31, 2022 | 99.99% |
November 30, 2022 | 99.99% |
October 31, 2022 | 99.99% |
September 30, 2022 | 99.99% |
August 31, 2022 | 99.99% |
July 31, 2022 | 99.99% |
June 30, 2022 | 99.99% |
May 31, 2022 | 99.99% |
Date | Value |
---|---|
April 30, 2022 | 99.99% |
March 31, 2022 | 99.99% |
February 28, 2022 | 99.99% |
January 31, 2022 | 99.99% |
December 31, 2021 | 99.99% |
November 30, 2021 | 99.99% |
October 31, 2021 | 99.99% |
September 30, 2021 | 99.99% |
August 31, 2021 | 99.53% |
July 31, 2021 | 99.71% |
June 30, 2021 | 99.76% |
May 31, 2021 | 99.88% |
April 30, 2021 | 99.88% |
March 31, 2021 | 99.88% |
February 28, 2021 | 99.88% |
January 31, 2021 | 99.88% |
December 31, 2020 | 99.88% |
November 30, 2020 | 99.88% |
October 31, 2020 | 99.88% |
September 30, 2020 | 99.88% |
August 31, 2020 | 99.88% |
July 31, 2020 | 99.88% |
June 30, 2020 | 99.88% |
May 31, 2020 | 99.88% |
April 30, 2020 | 99.88% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
99.53%
Minimum
Aug 2021
99.99%
Maximum
Sep 2021
99.93%
Average
99.99%
Median
Sep 2021
Max Drawdown (5Y) Benchmarks
CEL-SCI Corp | 96.13% |
AIM ImmunoTech Inc | 99.76% |
IGC Pharma Inc | 97.77% |
NovaBay Pharmaceuticals Inc | 99.91% |
Protalix BioTherapeutics Inc | 94.35% |